Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model

BJU International

Volumn 107, Issue 11, 2011, Pages 1818-1824

  Johansson, Anna ^a,b   Rudolfsson, Stina Häggström ^a   Kilter, Sigrid ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

castration; Dunning H; hypoxia; prostate; tirapazamine

Indexed keywords

ANDROGEN; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RELAPSE; CASTRATION; CELL HYPOXIA; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SEROLOGY; TARGET CELL DESTRUCTION; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANOXIA; APOPTOSIS; CELL HYPOXIA; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; ORCHIECTOMY; ORGAN CULTURE TECHNIQUES; OXYGEN CONSUMPTION; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS; STATISTICS, NONPARAMETRIC; TRIAZINES;

EID: 79956370477     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09690.x     Document Type: Article

References (49)

1. Harris AL,. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2 (1): 38-47 (Pubitemid 37328806)
2. Subarsky P, Hill RP,. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003; 20 (3): 237-50 (Pubitemid 36513228)
3. Graeber TG, Osmanian C, Jacks T, et al,. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379 (6560): 88-91 (Pubitemid 26008141)
4. Yu JL, Coomber BL, Kerbel RS,. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 2002; 70 (9-10): 599-609 (Pubitemid 36194324)
5. Ghafar MA, Anastasiadis AG, Chen MW, et al,. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate 2003; 54 (1): 58-67 (Pubitemid 36043837)
6. Butterworth KT, McCarthy HO, Devlin A, et al,. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer 2008; 123 (4): 760-8 (Pubitemid 352032400)
7. Rudolfsson SH, Bergh A,. Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets [Review] 2009; 13 (2): 219-25
8. Kerbel RS, Yu J, Tran J, et al,. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20 (1-2): 79-86 (Pubitemid 34074682)
9. Paez-Ribes M, Allen E, Hudock J, et al,. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15 (3): 220-31
10. Mazzone M, Dettori D, Leite de Oliveira R, et al,. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136 (5): 839-51
11. Ohlson N, Wikstrom P, Stattin P, Bergh A,. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 2005; 62 (4): 307-15 (Pubitemid 40224136)
12. Shabsigh A, Chang DT, Heitjan DF, et al,. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36 (3): 201-6 (Pubitemid 28341133)
13. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE,. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25 (5): 309-14 (Pubitemid 27461601)
14. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT,. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3 (12 Pt 1): 2507-11 (Pubitemid 28133175)
15. Haggstrom S, Wikstrom P, Bergh A, Damber JE,. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998; 36 (2): 71-9 (Pubitemid 28311310)
16. Johansson A, Rudolfsson SH, Wikstrom P, Bergh A,. Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 2005; 146 (8): 3463-70 (Pubitemid 41058119)
17. Shabsigh A, Ghafar MA, de la Taille A, et al,. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001; 81 (3): 437-44 (Pubitemid 32405761)
18. Rudolfsson SH, Bergh A,. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1alpha. J Endocrinol 2008; 196 (1): 11-9 (Pubitemid 351234567)
19. Stewart RJ, Panigrahy D, Flynn E, Folkman J,. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165 (2): 688-93 (Pubitemid 32060501)
20. Jain RK, Safabakhsh N, Sckell A, et al,. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95 (18): 10820-5 (Pubitemid 28413152)
21. Frost GI, Lustgarten J, Dudouet B, Nyberg L, Hartley-Asp B, Borgstrom P,. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res 2005; 69 (1-2): 1-9 (Pubitemid 40410462)
22. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al,. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000; 60 (16): 4556-60 (Pubitemid 32103640)
23. Parker C, Milosevic M, Toi A, et al,. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58 (3): 750-7 (Pubitemid 38221131)
24. Cvetkovic D, Movsas B, Dicker AP, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001; 57 (4): 821-5
25. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60 (4): 634-9 (Pubitemid 35246449)
26. Zhong H, Semenza GL, Simons JW, De Marzo AM,. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28 (2): 88-93 (Pubitemid 38448745)
27. Yeh KA, Biade S, Lanciano RM, et al,. Polarographic needle electrode measurements of oxygen in rat prostate carcinomas: accuracy and reproducibility. Int J Radiat Oncol Biol Phys 1995; 33 (1): 111-8
28. Brown JM, Wilson WR,. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4 (6): 437-47 (Pubitemid 38745529)
29. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI,. Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 2008; 75 (2): 247-55 (Pubitemid 351240940)
30. Emmenegger U, Morton GC, Francia G, et al,. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006; 66 (3): 1664-74 (Pubitemid 43259951)
31. Johansson A, Jones J, Pietras K, et al,. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. Prostate 2007; 67 (15): 1664-76 (Pubitemid 350036952)
32. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA,. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 2001; 49 (2): 569-74 (Pubitemid 32123612)
33. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A,. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139 (2): 451-6 (Pubitemid 28513188)
34. Lissbrant IF, Hammarsten P, Lissbrant E, Ferrara N, Rudolfsson SH, Bergh A,. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 2004; 58 (1): 57-65 (Pubitemid 38057989)
35. Halin S, Hammarsten P, Wikstrom P, Bergh A,. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 2007; 67 (4): 370-7 (Pubitemid 46341077)
36. Wikstrom P, Lindahl C, Bergh A,. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005; 62 (2): 148-64 (Pubitemid 40096781)
37. Hammarsten P, Halin S, Wikstom P, Henriksson R, Rudolfsson SH, Bergh A,. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 2006; 12 (24): 7431-6 (Pubitemid 46095418)
38. Durand RE, Aquino-Parsons C,. Clinical relevance of intermittent tumour blood flow. Acta Oncol 2001; 40 (8): 929-36 (Pubitemid 34098479)
39. Bacon AL, Harris AL,. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004; 36 (7): 530-9 (Pubitemid 39490962)
40. Gozal E, Sachleben LR Jr, Rane MJ, Vega C, Gozal D,. Mild sustained and intermittent hypoxia induce apoptosis in PC-12 cells via different mechanisms. Am J Physiol Cell Physiol 2005; 288 (3): C535-42 (Pubitemid 40229482)
41. Gao J, Arnold JT, Isaacs JT,. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 2001; 61 (13): 5038-44 (Pubitemid 32681532)
42. Shibata Y, Kashiwagi B, Arai S, et al,. Direct regulation of prostate blood flow by vascular endothelial growth factor and its participation in the androgenic regulation of prostate blood flow in vivo. Endocrinology 2004; 145 (10): 4507-12 (Pubitemid 39281442)
43. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK,. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91 (6): 512-23 (Pubitemid 29157059)
44. Gleave ME, Zellweger T, Chi K, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002; 20 (2): 145-58 (Pubitemid 34632652)
45. Westin P, Stattin P, Damber JE, Bergh A,. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995; 146 (6): 1368-75
46. Koivisto PA, Rantala I,. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 1999; 187 (2): 237-41 (Pubitemid 29037054)
47. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM,. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57 (21): 4687-91 (Pubitemid 27468967)
48. Wikstrom P, Marusic J, Stattin P, Bergh A,. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009; 69 (8): 799-809
49. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D,. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res 2004; 10 (24): 8728-34 (Pubitemid 40053442)